Clinical Trial Update: A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating ANS014004 in combination with an EGFR-TKI for Non-Small Cell Lung Cancer with EGFR mutations. The study is not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ANS014004

Snippet

Sponsor: Beijing Pearl Biotechnology Limited Liability Company | Conditions: Non-Small Cell Lung Cancer, EGFR Mutation | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING